Atlas Trials

Travere Therapeutics, Inc.

14 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Travere Therapeutics, Inc.

RecordFirmDate
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis (NCT07219121)Travere Therapeutics, Inc.2025-10-07
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (NCT06431893)Travere Therapeutics, Inc.2024-04-30
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment (NCT06247085)Travere Therapeutics, Inc.2023-12-28
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN (NCT05856760)Travere Therapeutics, Inc.2023-05-19
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) (NCT05200871)Travere Therapeutics, Inc.2022-02-05
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (NCT05003986)Travere Therapeutics, Inc.2021-08-12
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension (NCT05562362)Travere Therapeutics, Inc.2020-06-18
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) (NCT03406611)Travere Therapeutics, Inc.2019-01-22
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (NCT03762850)Travere Therapeutics, Inc.2018-12-11
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (NCT03493685)Travere Therapeutics, Inc.2018-04-17

Track Travere Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.